TELA Bio, Inc. (TELA) 10-Year Financial Performance & Capital Metrics

TELA • • Industrial / General

HealthcareMedical DevicesSurgical & Minimally Invasive DevicesSurgical Energy & Ablation Systems

AboutTELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.Show more

Revenue $69M +18.6%
EBITDA -$33M +23.5%
Net Income -$38M +18.9%
EPS (Diluted) -1.33 +34.8%
Gross Margin 67.08% -2.2%
EBITDA Margin -47.77% +35.5%
Operating Margin -49.23% +34.7%
Net Margin -54.6% +31.6%
ROE -159.87% +43.2%
ROIC -151.56% +34.3%
Debt/Equity 1.51 -33.2%
Interest Coverage -6.45 +23.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 35.0%
✓Trading at only 1.0x book value

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 16 (bottom 16%)
✗Shares diluted 24.7% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y35.02%

3Y32.99%

TTM12.24%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM6.08%

EPS CAGR

10Y-

5Y-

3Y-

TTM47.34%

ROCE

10Y Avg-80.07%

5Y Avg-56.03%

3Y Avg-66.55%

Latest-51.37%

Peer Comparison

Surgical Energy & Ablation Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
BDMDBaird Medical Investment Holdings Limited	47.38M	1.29	2.63	17.74%	33.62%	33%	0.53
IVFINVO Fertility, Inc.	12.26M	0.81	-0.03	116.25%	-417.01%	-495.09%	0.78
AEMDAethlon Medical, Inc.	2.55M	2.62	-0.03			-0.2%	0.13
HYPDHyperion DeFi, Inc.	29.01M	3.55	-0.06	14.14%	-73.86%	-36.05%
NAOVNanoVibronix, Inc.	1.85M	1.70	-0.12	12.05%	-133.04%	-8.41%	0.19
ALURAllurion Technologies Inc.	21.55M	1.76	-0.15	-39.94%	-251.56%
RBOTVicarious Surgical Inc.	18.23M	2.82	-0.26			-380.42%	0.30
TELATELA Bio, Inc.	44.98M	1.01	-0.76	18.56%	-50.61%	-25.05%	1.51

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	4.25M	8.27M	15.45M	18.21M	29.46M	41.42M	58.45M	69.3M
Revenue Growth %	-	0.95%	0.87%	0.18%	0.62%	0.41%	0.41%	0.19%
Cost of Goods Sold+	1.71M	5.33M	6.17M	6.98M	10.65M	14.37M	18.34M	22.81M
COGS % of Revenue	0.4%	0.64%	0.4%	0.38%	0.36%	0.35%	0.31%	0.33%
Gross Profit+	2.53M	2.94M	9.27M	11.23M	18.81M	27.04M	40.11M	46.49M
Gross Margin %	0.6%	0.36%	0.6%	0.62%	0.64%	0.65%	0.69%	0.67%
Gross Profit Growth %	-	0.16%	2.15%	0.21%	0.67%	0.44%	0.48%	0.16%
Operating Expenses+	19.46M	22.88M	28.43M	36.51M	48.26M	66.05M	84.19M	80.6M
OpEx % of Revenue	4.58%	2.77%	1.84%	2%	1.64%	1.59%	1.44%	1.16%
Selling, General & Admin	13.67M	18.55M	24.28M	32.25M	41.52M	57.11M	74.57M	79.37M
SG&A % of Revenue	3.22%	2.24%	1.57%	1.77%	1.41%	1.38%	1.28%	1.15%
Research & Development	5.79M	4.34M	4.15M	4.25M	6.74M	8.94M	9.62M	8.81M
R&D % of Revenue	1.36%	0.52%	0.27%	0.23%	0.23%	0.22%	0.16%	0.13%
Other Operating Expenses	94K	70K	0	0	0	0	0	-7.58M
Operating Income+	-16.92M	-17.78M	-19.16M	-25.27M	-29.45M	-39.01M	-44.08M	-34.12M
Operating Margin %	-3.99%	-2.15%	-1.24%	-1.39%	-1%	-0.94%	-0.75%	-0.49%
Operating Income Growth %	-	-0.05%	-0.08%	-0.32%	-0.17%	-0.32%	-0.13%	0.23%
EBITDA+	-16.16M	-16.53M	-18.58M	-24.75M	-28.92M	-37.82M	-43.27M	-33.1M
EBITDA Margin %	-3.81%	-2%	-1.2%	-1.36%	-0.98%	-0.91%	-0.74%	-0.48%
EBITDA Growth %	-	-0.02%	-0.12%	-0.33%	-0.17%	-0.31%	-0.14%	0.23%
D&A (Non-Cash Add-back)	761K	1.25M	582K	525K	535K	1.19M	808K	1.01M
EBIT	-16.78M	-19.29M	-18.82M	-25.23M	-29.68M	-40.24M	-41.44M	-32.7M
Net Interest Income+	-4.56M	-1.8M	-3.61M	-3.56M	-3.6M	-4.05M	-5.22M	-5.29M
Interest Income	0	0	0	0	0	0	0	0
Interest Expense	4.56M	1.8M	3.61M	3.56M	3.6M	4.05M	5.22M	5.29M
Other Income/Expense	-4.41M	-3.31M	-3.26M	-3.52M	-3.83M	-5.29M	-2.59M	-3.87M
Pretax Income+	-21.33M	-21.09M	-22.43M	-28.79M	-33.28M	-44.3M	-46.66M	-37.98M
Pretax Margin %	-5.03%	-2.55%	-1.45%	-1.58%	-1.13%	-1.07%	-0.8%	-0.55%
Income Tax+	0	0	0	0	0	0	0	-144K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-21.33M	-21.09M	-22.43M	-28.79M	-33.28M	-44.3M	-46.66M	-37.84M
Net Margin %	-5.03%	-2.55%	-1.45%	-1.58%	-1.13%	-1.07%	-0.8%	-0.55%
Net Income Growth %	-	0.01%	-0.06%	-0.28%	-0.16%	-0.33%	-0.05%	0.19%
Net Income (Continuing)	-21.33M	-21.09M	-22.43M	-28.79M	-33.28M	-44.3M	-46.66M	-37.84M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-3.29	-3.25	-2.26	-2.23	-2.30	-2.73	-2.04	-1.33
EPS Growth %	-	0.01%	0.3%	0.01%	-0.03%	-0.19%	0.25%	0.35%
EPS (Basic)	-3.29	-3.25	-2.26	-2.23	-2.30	-2.73	-2.04	-1.33
Diluted Shares Outstanding	6.49M	6.49M	11.41M	12.93M	14.47M	16.27M	22.87M	28.53M
Basic Shares Outstanding	6.49M	6.49M	11.41M	12.93M	14.47M	16.27M	22.87M	28.53M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	14.35M	23.25M	64.33M	83.22M	59.05M	62.45M	71.73M	78.07M
Cash & Short-Term Investments	11.35M	17.28M	54.59M	74.39M	43.93M	42.02M	46.73M	52.67M
Cash Only	11.35M	17.28M	45.3M	74.39M	43.93M	42.02M	46.73M	52.67M
Short-Term Investments	0	0	9.29M	0	0	0	0	0
Accounts Receivable	757K	1.3M	2.84M	2.68M	4.23M	6.62M	9.74M	10.1M
Days Sales Outstanding	65.09	57.26	67.02	53.77	52.45	58.35	60.8	53.19
Inventory	1.81M	4.35M	4.6M	3.91M	7.66M	11.79M	13.16M	12.78M
Days Inventory Outstanding	386.73	297.64	272.12	204.34	262.46	299.44	261.93	204.5
Other Current Assets	0	0	0	0	0	2.02M	2.1M	2.52M
Total Non-Current Assets+	1.19M	3.97M	3.59M	3.23M	3.49M	5.41M	6.32M	9.25M
Property, Plant & Equipment	1.16M	758K	677K	626K	1.19M	2.91M	3.94M	4.08M
Fixed Asset Turnover	3.66x	10.92x	22.82x	29.09x	24.84x	14.24x	14.84x	16.99x
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	3.21M	2.91M	2.61M	2.3M	2.5M	2.12M	1.74M
Long-Term Investments	24K	0	0	0	0	0	265K	2.54M
Other Non-Current Assets	0	0	0	0	0	0	0	0
Total Assets+	15.53M	27.23M	67.92M	86.46M	62.54M	67.86M	78.05M	87.33M
Asset Turnover	0.27x	0.30x	0.23x	0.21x	0.47x	0.61x	0.75x	0.79x
Asset Growth %	-	0.75%	1.49%	0.27%	-0.28%	0.08%	0.15%	0.12%
Total Current Liabilities+	6.15M	9.56M	6.71M	6.61M	10.57M	12.4M	16.97M	15.6M
Accounts Payable	1.51M	3.42M	3.17M	652K	2.41M	1.53M	1.67M	2.15M
Days Payables Outstanding	321.11	234.18	187.47	34.1	82.73	38.95	33.17	34.35
Short-Term Debt	905K	0	0	0	0	340K	565K	545K
Deferred Revenue (Current)	1000K	0	0	0	0	0	0	0
Other Current Liabilities	1.94M	985K	1.19M	2.24M	3.15M	4.11M	5.52M	5.56M
Current Ratio	2.33x	2.43x	9.58x	12.60x	5.58x	5.03x	4.23x	5.01x
Quick Ratio	2.04x	1.98x	8.90x	12.01x	4.86x	4.08x	3.45x	4.19x
Cash Conversion Cycle	130.72	120.72	151.67	224	232.18	318.83	289.56	223.33
Total Non-Current Liabilities+	117.56M	155.53M	30.25M	30.83M	31.87M	41.15M	42.2M	43.27M
Long-Term Debt	3.61M	29.73M	30.24M	30.83M	31.49M	39.92M	40.52M	41.12M
Capital Lease Obligations	0	0	0	0	0	1.2M	1.69M	1.39M
Deferred Tax Liabilities	0	0	0	0	0	0	0	756K
Other Non-Current Liabilities	113.94M	125.8M	4K	0	380K	31K	0	0
Total Liabilities	123.7M	165.09M	36.96M	37.43M	42.45M	53.55M	59.17M	58.87M
Total Debt+	4.51M	29.73M	30.24M	30.83M	31.49M	41.46M	42.77M	43.06M
Net Debt	-6.83M	12.46M	-15.06M	-43.57M	-12.44M	-563K	-3.96M	-9.61M
Debt / Equity	-	-	0.98x	0.63x	1.57x	2.90x	2.26x	1.51x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-3.71x	-9.87x	-5.31x	-7.09x	-8.19x	-9.63x	-8.44x	-6.45x
Total Equity+	-108.17M	-137.86M	30.96M	49.03M	20.1M	14.3M	18.88M	28.46M
Equity Growth %	-	-0.27%	1.22%	0.58%	-0.59%	-0.29%	0.32%	0.51%
Book Value per Share	-16.67	-21.25	2.71	3.79	1.39	0.88	0.83	1.00
Total Shareholders' Equity	-108.17M	-137.86M	30.96M	49.03M	20.1M	14.3M	18.88M	28.46M
Common Stock	7K	0	11K	14K	15K	19K	24K	39K
Retained Earnings	-108.17M	-137.86M	-167.86M	-196.65M	-229.93M	-274.23M	-320.89M	-358.73M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	-2.79M	-3.24M	-19K	-71K	-52K	150K	91K	90K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-16.37M	-19.92M	-25.52M	-24.46M	-30.43M	-40.75M	-40.86M	-41.59M
Operating CF Margin %	-3.86%	-2.41%	-1.65%	-1.34%	-1.03%	-0.98%	-0.7%	-0.6%
Operating CF Growth %	-	-0.22%	-0.28%	0.04%	-0.24%	-0.34%	-0%	-0.02%
Net Income	-21.33M	-21.09M	-22.43M	-28.79M	-33.28M	-44.3M	-46.66M	-37.84M
Depreciation & Amortization	761K	1.25M	582K	525K	535K	1.19M	808K	1.01M
Stock-Based Compensation	197K	216K	457K	2.06M	3.66M	3.99M	5.03M	4.36M
Deferred Taxes	-40K	1.22M	5K	0	14K	0	0	-144K
Other Non-Cash Items	3.97M	2.94M	2.09M	1.84M	2.1M	4.13M	1.64M	-4.12M
Working Capital Changes	75K	-4.46M	-6.24M	-86K	-3.47M	-5.76M	-1.67M	-4.87M
Change in Receivables	-578K	-541K	-1.53M	149K	-1.55M	-2.42M	-3.06M	-762K
Change in Inventory	-127K	-4.76M	-1.84M	-620K	-5.19M	-6.07M	-2.72M	-2.97M
Change in Payables	-748K	1.91M	-773K	-2M	1.6M	-884K	11K	482K
Cash from Investing+	-101K	-1.56M	-11.98M	9.12M	-627K	-1.87M	-599K	4.45M
Capital Expenditures	-114K	-1.56M	-2.7M	-167K	-627K	-872K	-611K	0
CapEx % of Revenue	0.03%	0.19%	0.17%	0.01%	0.02%	0.02%	0.01%	0.01%
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	13K	4K	0	0	0	-1M	12K	4.45M
Cash from Financing+	26.34M	27.41M	65.53M	44.41M	585K	40.85M	46.27M	43.06M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	14.14M	-1.56M	14K	-313K	0	-3.55M	-74K	138K
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-16.48M	-21.49M	-28.22M	-24.62M	-31.06M	-42.62M	-41.47M	-42.58M
FCF Margin %	-3.88%	-2.6%	-1.83%	-1.35%	-1.05%	-1.03%	-0.71%	-0.61%
FCF Growth %	-	-0.3%	-0.31%	0.13%	-0.26%	-0.37%	0.03%	-0.03%
FCF per Share	-2.54	-3.31	-2.47	-1.90	-2.15	-2.62	-1.81	-1.49
FCF Conversion (FCF/Net Income)	0.77x	0.94x	1.14x	0.85x	0.91x	0.92x	0.88x	1.10x
Interest Paid	0	0	0	2.98M	0	3.39M	4.62M	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-72.43%	-72%	-96.28%	-257.51%	-281.23%	-159.87%
Return on Invested Capital (ROIC)	-	-	-	-177.48%	-336.79%	-273.41%	-230.69%	-151.56%
Gross Margin	59.65%	35.56%	60.03%	61.68%	63.85%	65.3%	68.62%	67.08%
Net Margin	-502.57%	-254.92%	-145.18%	-158.1%	-112.94%	-106.95%	-79.83%	-54.6%
Debt / Equity	-	-	0.98x	0.63x	1.57x	2.90x	2.26x	1.51x
Interest Coverage	-3.71x	-9.87x	-5.31x	-7.09x	-8.19x	-9.63x	-8.44x	-6.45x
FCF Conversion	0.77x	0.94x	1.14x	0.85x	0.91x	0.92x	0.88x	1.10x
Revenue Growth	-	94.91%	86.68%	17.91%	61.77%	40.58%	41.13%	18.56%

Revenue by Geography

	2019	2022	2023	2024
Non-US	-	3.2M	6.1M	10.3M
Non-US Growth	-	-	90.63%	68.85%
Europe	500K	-	-	-
Europe Growth	-	-	-	-

Frequently Asked Questions

Growth & Financials

TELA Bio, Inc. (TELA) reported $77.1M in revenue for fiscal year 2024. This represents a 1715% increase from $4.2M in 2017.

TELA Bio, Inc. (TELA) grew revenue by 18.6% over the past year. This is strong growth.

TELA Bio, Inc. (TELA) reported a net loss of $39.0M for fiscal year 2024.

Dividend & Returns

TELA Bio, Inc. (TELA) has a return on equity (ROE) of -159.9%. Negative ROE indicates the company is unprofitable.

TELA Bio, Inc. (TELA) had negative free cash flow of $31.5M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

TELA Bio, Inc. (TELA) 10-Year Financial Performance & Capital Metrics

TELA • • Industrial / General

HealthcareMedical DevicesSurgical & Minimally Invasive DevicesSurgical Energy & Ablation Systems

Revenue $69M +18.6%
EBITDA -$33M +23.5%
Net Income -$38M +18.9%
EPS (Diluted) -1.33 +34.8%
Gross Margin 67.08% -2.2%
EBITDA Margin -47.77% +35.5%
Operating Margin -49.23% +34.7%
Net Margin -54.6% +31.6%
ROE -159.87% +43.2%
ROIC -151.56% +34.3%
Debt/Equity 1.51 -33.2%
Interest Coverage -6.45 +23.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 35.0%
✓Trading at only 1.0x book value

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 16 (bottom 16%)
✗Shares diluted 24.7% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y35.02%

3Y32.99%

TTM12.24%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM6.08%

EPS CAGR

10Y-

5Y-

3Y-

TTM47.34%

ROCE

10Y Avg-80.07%

5Y Avg-56.03%

3Y Avg-66.55%

Latest-51.37%

Peer Comparison

Surgical Energy & Ablation Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
BDMDBaird Medical Investment Holdings Limited	47.38M	1.29	2.63	17.74%	33.62%	33%	0.53
IVFINVO Fertility, Inc.	12.26M	0.81	-0.03	116.25%	-417.01%	-495.09%	0.78
AEMDAethlon Medical, Inc.	2.55M	2.62	-0.03			-0.2%	0.13
HYPDHyperion DeFi, Inc.	29.01M	3.55	-0.06	14.14%	-73.86%	-36.05%
NAOVNanoVibronix, Inc.	1.85M	1.70	-0.12	12.05%	-133.04%	-8.41%	0.19
ALURAllurion Technologies Inc.	21.55M	1.76	-0.15	-39.94%	-251.56%
RBOTVicarious Surgical Inc.	18.23M	2.82	-0.26			-380.42%	0.30
TELATELA Bio, Inc.	44.98M	1.01	-0.76	18.56%	-50.61%	-25.05%	1.51

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	4.25M	8.27M	15.45M	18.21M	29.46M	41.42M	58.45M	69.3M
Revenue Growth %	-	0.95%	0.87%	0.18%	0.62%	0.41%	0.41%	0.19%
Cost of Goods Sold+	1.71M	5.33M	6.17M	6.98M	10.65M	14.37M	18.34M	22.81M
COGS % of Revenue	0.4%	0.64%	0.4%	0.38%	0.36%	0.35%	0.31%	0.33%
Gross Profit+	2.53M	2.94M	9.27M	11.23M	18.81M	27.04M	40.11M	46.49M
Gross Margin %	0.6%	0.36%	0.6%	0.62%	0.64%	0.65%	0.69%	0.67%
Gross Profit Growth %	-	0.16%	2.15%	0.21%	0.67%	0.44%	0.48%	0.16%
Operating Expenses+	19.46M	22.88M	28.43M	36.51M	48.26M	66.05M	84.19M	80.6M
OpEx % of Revenue	4.58%	2.77%	1.84%	2%	1.64%	1.59%	1.44%	1.16%
Selling, General & Admin	13.67M	18.55M	24.28M	32.25M	41.52M	57.11M	74.57M	79.37M
SG&A % of Revenue	3.22%	2.24%	1.57%	1.77%	1.41%	1.38%	1.28%	1.15%
Research & Development	5.79M	4.34M	4.15M	4.25M	6.74M	8.94M	9.62M	8.81M
R&D % of Revenue	1.36%	0.52%	0.27%	0.23%	0.23%	0.22%	0.16%	0.13%
Other Operating Expenses	94K	70K	0	0	0	0	0	-7.58M
Operating Income+	-16.92M	-17.78M	-19.16M	-25.27M	-29.45M	-39.01M	-44.08M	-34.12M
Operating Margin %	-3.99%	-2.15%	-1.24%	-1.39%	-1%	-0.94%	-0.75%	-0.49%
Operating Income Growth %	-	-0.05%	-0.08%	-0.32%	-0.17%	-0.32%	-0.13%	0.23%
EBITDA+	-16.16M	-16.53M	-18.58M	-24.75M	-28.92M	-37.82M	-43.27M	-33.1M
EBITDA Margin %	-3.81%	-2%	-1.2%	-1.36%	-0.98%	-0.91%	-0.74%	-0.48%
EBITDA Growth %	-	-0.02%	-0.12%	-0.33%	-0.17%	-0.31%	-0.14%	0.23%
D&A (Non-Cash Add-back)	761K	1.25M	582K	525K	535K	1.19M	808K	1.01M
EBIT	-16.78M	-19.29M	-18.82M	-25.23M	-29.68M	-40.24M	-41.44M	-32.7M
Net Interest Income+	-4.56M	-1.8M	-3.61M	-3.56M	-3.6M	-4.05M	-5.22M	-5.29M
Interest Income	0	0	0	0	0	0	0	0
Interest Expense	4.56M	1.8M	3.61M	3.56M	3.6M	4.05M	5.22M	5.29M
Other Income/Expense	-4.41M	-3.31M	-3.26M	-3.52M	-3.83M	-5.29M	-2.59M	-3.87M
Pretax Income+	-21.33M	-21.09M	-22.43M	-28.79M	-33.28M	-44.3M	-46.66M	-37.98M
Pretax Margin %	-5.03%	-2.55%	-1.45%	-1.58%	-1.13%	-1.07%	-0.8%	-0.55%
Income Tax+	0	0	0	0	0	0	0	-144K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-21.33M	-21.09M	-22.43M	-28.79M	-33.28M	-44.3M	-46.66M	-37.84M
Net Margin %	-5.03%	-2.55%	-1.45%	-1.58%	-1.13%	-1.07%	-0.8%	-0.55%
Net Income Growth %	-	0.01%	-0.06%	-0.28%	-0.16%	-0.33%	-0.05%	0.19%
Net Income (Continuing)	-21.33M	-21.09M	-22.43M	-28.79M	-33.28M	-44.3M	-46.66M	-37.84M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-3.29	-3.25	-2.26	-2.23	-2.30	-2.73	-2.04	-1.33
EPS Growth %	-	0.01%	0.3%	0.01%	-0.03%	-0.19%	0.25%	0.35%
EPS (Basic)	-3.29	-3.25	-2.26	-2.23	-2.30	-2.73	-2.04	-1.33
Diluted Shares Outstanding	6.49M	6.49M	11.41M	12.93M	14.47M	16.27M	22.87M	28.53M
Basic Shares Outstanding	6.49M	6.49M	11.41M	12.93M	14.47M	16.27M	22.87M	28.53M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	14.35M	23.25M	64.33M	83.22M	59.05M	62.45M	71.73M	78.07M
Cash & Short-Term Investments	11.35M	17.28M	54.59M	74.39M	43.93M	42.02M	46.73M	52.67M
Cash Only	11.35M	17.28M	45.3M	74.39M	43.93M	42.02M	46.73M	52.67M
Short-Term Investments	0	0	9.29M	0	0	0	0	0
Accounts Receivable	757K	1.3M	2.84M	2.68M	4.23M	6.62M	9.74M	10.1M
Days Sales Outstanding	65.09	57.26	67.02	53.77	52.45	58.35	60.8	53.19
Inventory	1.81M	4.35M	4.6M	3.91M	7.66M	11.79M	13.16M	12.78M
Days Inventory Outstanding	386.73	297.64	272.12	204.34	262.46	299.44	261.93	204.5
Other Current Assets	0	0	0	0	0	2.02M	2.1M	2.52M
Total Non-Current Assets+	1.19M	3.97M	3.59M	3.23M	3.49M	5.41M	6.32M	9.25M
Property, Plant & Equipment	1.16M	758K	677K	626K	1.19M	2.91M	3.94M	4.08M
Fixed Asset Turnover	3.66x	10.92x	22.82x	29.09x	24.84x	14.24x	14.84x	16.99x
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	3.21M	2.91M	2.61M	2.3M	2.5M	2.12M	1.74M
Long-Term Investments	24K	0	0	0	0	0	265K	2.54M
Other Non-Current Assets	0	0	0	0	0	0	0	0
Total Assets+	15.53M	27.23M	67.92M	86.46M	62.54M	67.86M	78.05M	87.33M
Asset Turnover	0.27x	0.30x	0.23x	0.21x	0.47x	0.61x	0.75x	0.79x
Asset Growth %	-	0.75%	1.49%	0.27%	-0.28%	0.08%	0.15%	0.12%
Total Current Liabilities+	6.15M	9.56M	6.71M	6.61M	10.57M	12.4M	16.97M	15.6M
Accounts Payable	1.51M	3.42M	3.17M	652K	2.41M	1.53M	1.67M	2.15M
Days Payables Outstanding	321.11	234.18	187.47	34.1	82.73	38.95	33.17	34.35
Short-Term Debt	905K	0	0	0	0	340K	565K	545K
Deferred Revenue (Current)	1000K	0	0	0	0	0	0	0
Other Current Liabilities	1.94M	985K	1.19M	2.24M	3.15M	4.11M	5.52M	5.56M
Current Ratio	2.33x	2.43x	9.58x	12.60x	5.58x	5.03x	4.23x	5.01x
Quick Ratio	2.04x	1.98x	8.90x	12.01x	4.86x	4.08x	3.45x	4.19x
Cash Conversion Cycle	130.72	120.72	151.67	224	232.18	318.83	289.56	223.33
Total Non-Current Liabilities+	117.56M	155.53M	30.25M	30.83M	31.87M	41.15M	42.2M	43.27M
Long-Term Debt	3.61M	29.73M	30.24M	30.83M	31.49M	39.92M	40.52M	41.12M
Capital Lease Obligations	0	0	0	0	0	1.2M	1.69M	1.39M
Deferred Tax Liabilities	0	0	0	0	0	0	0	756K
Other Non-Current Liabilities	113.94M	125.8M	4K	0	380K	31K	0	0
Total Liabilities	123.7M	165.09M	36.96M	37.43M	42.45M	53.55M	59.17M	58.87M
Total Debt+	4.51M	29.73M	30.24M	30.83M	31.49M	41.46M	42.77M	43.06M
Net Debt	-6.83M	12.46M	-15.06M	-43.57M	-12.44M	-563K	-3.96M	-9.61M
Debt / Equity	-	-	0.98x	0.63x	1.57x	2.90x	2.26x	1.51x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-3.71x	-9.87x	-5.31x	-7.09x	-8.19x	-9.63x	-8.44x	-6.45x
Total Equity+	-108.17M	-137.86M	30.96M	49.03M	20.1M	14.3M	18.88M	28.46M
Equity Growth %	-	-0.27%	1.22%	0.58%	-0.59%	-0.29%	0.32%	0.51%
Book Value per Share	-16.67	-21.25	2.71	3.79	1.39	0.88	0.83	1.00
Total Shareholders' Equity	-108.17M	-137.86M	30.96M	49.03M	20.1M	14.3M	18.88M	28.46M
Common Stock	7K	0	11K	14K	15K	19K	24K	39K
Retained Earnings	-108.17M	-137.86M	-167.86M	-196.65M	-229.93M	-274.23M	-320.89M	-358.73M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	-2.79M	-3.24M	-19K	-71K	-52K	150K	91K	90K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-16.37M	-19.92M	-25.52M	-24.46M	-30.43M	-40.75M	-40.86M	-41.59M
Operating CF Margin %	-3.86%	-2.41%	-1.65%	-1.34%	-1.03%	-0.98%	-0.7%	-0.6%
Operating CF Growth %	-	-0.22%	-0.28%	0.04%	-0.24%	-0.34%	-0%	-0.02%
Net Income	-21.33M	-21.09M	-22.43M	-28.79M	-33.28M	-44.3M	-46.66M	-37.84M
Depreciation & Amortization	761K	1.25M	582K	525K	535K	1.19M	808K	1.01M
Stock-Based Compensation	197K	216K	457K	2.06M	3.66M	3.99M	5.03M	4.36M
Deferred Taxes	-40K	1.22M	5K	0	14K	0	0	-144K
Other Non-Cash Items	3.97M	2.94M	2.09M	1.84M	2.1M	4.13M	1.64M	-4.12M
Working Capital Changes	75K	-4.46M	-6.24M	-86K	-3.47M	-5.76M	-1.67M	-4.87M
Change in Receivables	-578K	-541K	-1.53M	149K	-1.55M	-2.42M	-3.06M	-762K
Change in Inventory	-127K	-4.76M	-1.84M	-620K	-5.19M	-6.07M	-2.72M	-2.97M
Change in Payables	-748K	1.91M	-773K	-2M	1.6M	-884K	11K	482K
Cash from Investing+	-101K	-1.56M	-11.98M	9.12M	-627K	-1.87M	-599K	4.45M
Capital Expenditures	-114K	-1.56M	-2.7M	-167K	-627K	-872K	-611K	0
CapEx % of Revenue	0.03%	0.19%	0.17%	0.01%	0.02%	0.02%	0.01%	0.01%
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	13K	4K	0	0	0	-1M	12K	4.45M
Cash from Financing+	26.34M	27.41M	65.53M	44.41M	585K	40.85M	46.27M	43.06M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	14.14M	-1.56M	14K	-313K	0	-3.55M	-74K	138K
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-16.48M	-21.49M	-28.22M	-24.62M	-31.06M	-42.62M	-41.47M	-42.58M
FCF Margin %	-3.88%	-2.6%	-1.83%	-1.35%	-1.05%	-1.03%	-0.71%	-0.61%
FCF Growth %	-	-0.3%	-0.31%	0.13%	-0.26%	-0.37%	0.03%	-0.03%
FCF per Share	-2.54	-3.31	-2.47	-1.90	-2.15	-2.62	-1.81	-1.49
FCF Conversion (FCF/Net Income)	0.77x	0.94x	1.14x	0.85x	0.91x	0.92x	0.88x	1.10x
Interest Paid	0	0	0	2.98M	0	3.39M	4.62M	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-72.43%	-72%	-96.28%	-257.51%	-281.23%	-159.87%
Return on Invested Capital (ROIC)	-	-	-	-177.48%	-336.79%	-273.41%	-230.69%	-151.56%
Gross Margin	59.65%	35.56%	60.03%	61.68%	63.85%	65.3%	68.62%	67.08%
Net Margin	-502.57%	-254.92%	-145.18%	-158.1%	-112.94%	-106.95%	-79.83%	-54.6%
Debt / Equity	-	-	0.98x	0.63x	1.57x	2.90x	2.26x	1.51x
Interest Coverage	-3.71x	-9.87x	-5.31x	-7.09x	-8.19x	-9.63x	-8.44x	-6.45x
FCF Conversion	0.77x	0.94x	1.14x	0.85x	0.91x	0.92x	0.88x	1.10x
Revenue Growth	-	94.91%	86.68%	17.91%	61.77%	40.58%	41.13%	18.56%

Revenue by Geography

	2019	2022	2023	2024
Non-US	-	3.2M	6.1M	10.3M
Non-US Growth	-	-	90.63%	68.85%
Europe	500K	-	-	-
Europe Growth	-	-	-	-

Frequently Asked Questions

Growth & Financials

TELA Bio, Inc. (TELA) reported $77.1M in revenue for fiscal year 2024. This represents a 1715% increase from $4.2M in 2017.

TELA Bio, Inc. (TELA) grew revenue by 18.6% over the past year. This is strong growth.

TELA Bio, Inc. (TELA) reported a net loss of $39.0M for fiscal year 2024.

Dividend & Returns

TELA Bio, Inc. (TELA) has a return on equity (ROE) of -159.9%. Negative ROE indicates the company is unprofitable.

TELA Bio, Inc. (TELA) had negative free cash flow of $31.5M in fiscal year 2024, likely due to heavy capital investments.